G
Gilbert Wagener
Researcher at Bayer
Publications - 14
Citations - 946
Gilbert Wagener is an academic researcher from Bayer. The author has contributed to research in topics: Nifedipine & Myocardial infarction. The author has an hindex of 8, co-authored 14 publications receiving 917 citations. Previous affiliations of Gilbert Wagener include SOCAR & Bayer Corporation.
Papers
More filters
Journal ArticleDOI
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomised controlled trial
Philip A. Poole-Wilson,Jacobus Lubsen,Bridget-Anne Kirwan,Fred J van Dalen,Gilbert Wagener,Nicolas Danchin,Hanjörg Just,Keith A.A. Fox,Stuart J. Pocock,Tim Clayton,Michael Motro,John D. Parker,Martial G. Bourassa,Anthony M. Dart,Per Hildebrandt,Åke Hjalmarson,Johannes A. Kragten,G Peter Molhoek,J.E. Otterstad,Ricardo Seabra-Gomes,Jordi Soler-Soler,Simon Weber +21 more
TL;DR: Addition of nifedipine GITS to conventional treatment of angina pectoris has no effect on major cardiovascular event-free survival and is safe and reduces the need for coronary angiography and interventions.
Journal ArticleDOI
Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)
Giuseppe Mancia,Morris J. Brown,Alain Castaigne,Peter W. de Leeuw,Christopher R. Palmer,Talma Rosenthal,Gilbert Wagener,Luis M. Ruilope +7 more
TL;DR: Nifedipine GITS once daily is as effective as diuretic therapy in reducing cardiovascular complications in hypertensive diabetics and could be considered as first-line therapy for hypertensiveDiabetics.
Journal ArticleDOI
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial
TL;DR: The salutary effects of the addition of nifedipine GITS to the basic regimen of patients with concurrent stable symptomatic coronary artery disease and hypertension emphasize the need for blood pressure control.
Journal ArticleDOI
Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial.
Peter W. de Leeuw,Luis M. Ruilope,Christopher R. Palmer,Morris J. Brown,Alain Castaigne,Giuseppe Mancia,Talma Rosenthal,Gilbert Wagener +7 more
TL;DR: Renal function is an important predictor of risk in hypertensive patients at high risk and antihypertensive treatment with a long-acting dihydropyridine calcium channel blocker may better preserve renal function than would treatment with diuretics.
Journal ArticleDOI
Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome.
Luis M. Ruilope,Bridget-Anne Kirwan,Sophie de Brouwer,Nicolas Danchin,Keith A.A. Fox,Gilbert Wagener,Julian Segura,Philip A. Poole-Wilson,Jacobus Lubsen +8 more
TL;DR: It is concluded that, in patients with stable angina, nifedipine reduces uric acid levels and does not affect other markers of renal dysfunction, and Renal dysfunction does not alter the effects of nifingipine on clinical outcome.